Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Form 8-K

sec.gov

8-K — CODEXIS, INC.

Accession: 0001193125-26-458492

Filed: 2026-11-12

Period: 2026-11-12

CIK: 0001200375

SIC: 2860 (INDUSTRIAL ORGANIC CHEMICALS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — d189706d8k.htm (Primary)

EX-99.1 (d189706dex991.htm)

GRAPHIC (g189706g1113012950841.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: d189706d8k.htm · Sequence: 1

8-K

false 0001200375 0001200375 2026-11-12 2026-11-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2026

Codexis, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-34705

71-0872999

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

200 Penobscot Drive

Redwood City, CA 94063

(Address of Principal Executive Offices) (Zip Code)

(650) 421-8100

Registrant’s telephone number, including area code

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading

Symbol(s)

Name of Each Exchange

on Which Registered

Common Stock, par value $0.0001 per share

CDXS

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02

Results of Operations and Financial Condition.

On November 12, 2026, Codexis, Inc. announced its financial results for the quarter ended September 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Item 9.01

Financial Statements and Exhibits.

Exhibit

No.

Description

99.1

Press release dated November 12, 2026 relating to the financial results for the quarter ended September 30, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CODEXIS, INC.

Date: November 12, 2026

By:

/s/ Georgia Erbez

Georgia Erbez

Chief Financial Officer and Chief Business Officer

EX-99.1

EX-99.1

Filename: d189706dex991.htm · Sequence: 2

EX-99.1

Exhibit 99.1

Codexis, Inc.

200 Penobscot Drive

Redwood City, CA 94063

+1 (650)

421-8100

codexis.com

Codexis Reports Third Quarter 2026 Financial Results and Provides Business Update

Reports revenue of $19.3 million for the third quarter of 2026, company reiterates full-year revenue guidance

Shared new advances in RNA therapeutic manufacturing at TIDES Europe

Entered into a $60 million term loan facility with Trinity Capital; initial tranche used to refinance current debt

REDWOOD CITY, Calif., November 12, 2026 — Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for

efficient and scalable manufacturing of complex therapeutics, today announced financial results for the third quarter ended September 30, 2026, and provided a business update.

“I am pleased with our outstanding progress in 2026, through both innovation and technical achievements, that has garnered attention from leading

innovators in the siRNA field,” stated Alison Moore, PhD, President and Chief Executive Officer of Codexis. “Last week we presented new data at the TIDES Europe annual meeting showing successful

scale-up of the ECO Synthesis® Manufacturing Platform at 100-gram scale with high product quality, and including

improved process performance with reduced cycle time. In addition, we significantly strengthened our balance sheet with an equity raise of approximately $25 million in net proceeds, completed in July. This was followed by a $60 million

term loan agreement which we closed earlier this month, of which $42.5 million was used to refinance our existing debt. We have made significant progress in industrializing our technology while simultaneously increasing our revenue base,

managing expenses, and improving the financial stability of our company.”

Third Quarter and Recent Business Highlights

•

In November, the company completed a $60 million senior secured loan agreement with Trinity Capital. The

first tranche of $42.5 million was used to replace the existing agreement the company had with Innovatus Life Sciences Lending Fund I, LP. The remainder of the facility is available for future drawdown, subject to certain conditions.

•

In November, Codexis hosted key presentations at the 2026 TIDES Europe annual meeting. These presentations

demonstrated successful production of 100 grams of high-quality oligonucleotide. The company also showed greater potency of stereo-defined siRNA as compared to chemically synthesized material. These presentations have continued to expand

industry-wide interest in the ECO Synthesis Manufacturing Platform.

•

In October, Codexis announced a feasibility study with a pioneer company in the siRNA field, where Codexis will

use its ECO Synthesis technology to synthesize stereo-defined fragments. This innovator uses a fragment synthesis and ligation strategy and is seeking a method to increase the purity of fragments above what can be attained using standard solid phase

chemistry techniques.

•

The company successfully completed an equity financing in July that raised a total of approximately

$25 million in net proceeds.

Upcoming Milestones

•

Advance its partnerships with drug innovators toward clinical stage manufacturing agreements.

•

Codexis expects to begin retrofit construction for its ECO GMP Manufacturing Center in the new year, with the

facility being operational by the end of 2027. The purpose of this facility is to provide siRNA material for preclinical investigations and Phase 1 and 2 clinical trials.

•

Expand relationships with existing and future CDMO partners with a goal of commencing a strategic partner

agreement.

Third Quarter 2026 Financial Highlights

•

Total revenues were $19.3 million for the third quarter of 2026 compared to $8.6 million in the third

quarter of 2025. The increase was primarily due to higher product revenue, driven by the approval and launch of new products by our customers with higher margins compared to more established products.

•

Product gross margin was 74.5% for the third quarter of 2026, compared to 64% in the third quarter of 2025. The

increase in gross margin was largely due to a shift in sales toward more profitable products, and declines in less profitable, established products.

•

Research and Development expenses for the third quarter of 2026 were $12.6 million compared to

$13.9 million in the third quarter of 2025. The decrease was primarily due to lower employee-related costs, reduced spending on outside services and lower lab supplies, partially offset by higher allocable costs.

•

Selling, General & Administrative expenses for the third quarter of 2026 were $10.1 million

compared to $11.2 million in the third quarter of 2025. The decrease was primarily due to lower employee-related costs associated with reduced headcount, lower stock-based compensation expenses, and lower allocable costs, partially offset by

higher facility-related expenses.

•

The net loss for the third quarter of 2026 was $8.1 million, or $0.08 per share, compared to a net loss of

$19.6 million, or $0.22 per share, for the third quarter of 2025.

•

As of September 30, 2026, Codexis had $72.7 million in cash, cash equivalents, and short-term

investments. During the third quarter, Codexis successfully completed an equity financing that raised a total of approximately $25 million in net proceeds. In addition, after the close of the third quarter Codexis entered into a

$60 million term loan facility with a $42.5 million drawdown at closing, which was used to retire existing debt.

2026

Financial Revenue Guidance Reiterated, Gross Margin Estimate Increased

Codexis reiterated and updated its full-year 2026 financial guidance as

follows:

•

Total revenues are expected to be in the range of $72 million to $76 million. Gross margin for the year

2026 is expected to be in the low 70% range.

•

Codexis expects that its existing cash, cash equivalents, and short-term investments will be sufficient to fund

its planned operations through the end of 2028. The financial guidance and cash runway projections include the expenses associated with the build out of the GMP production facility.

Page | 2

Conference Call and Webcast

Codexis will hold a conference call and webcast today beginning at 4:30 pm ET. A live webcast will be available on the Investors section of the Company website

at ir.codexis.com. The conference call dial-in numbers are 877-705-2976 for domestic callers and 201-689-8798 for international callers.

A webcast replay will be available on

the Investors section of the Company website, beginning approximately two hours after the completion of the call.

About Codexis

Codexis® is a leading provider of high-performance enzymatic solutions for efficient and scalable

therapeutics manufacturing. The company is currently developing its proprietary ECO Synthesis® Manufacturing Platform, an aqueous enzymatic process that may offer a scalable alternative to

traditional solid phase organic synthesis of oligonucleotide manufacturing. Initially, Codexis is applying its technology to address the rapidly growing demand for RNAi therapeutics. Codexis’ unique enzymes can drive improvements such as

higher yields, increased purity, reduced energy usage and waste generation, stereoisomer control of siRNA, and improved overall capacity in manufacturing at substantially lower capital requirements, all of which may lead to greater efficiency and

reduced costs. In addition, the company supplies high-performance enzymes through its BioCatalysis business that are used in the manufacture of multiple commercially available small molecule therapeutics. For additional information, please visit

https://www.codexis.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E

of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,”

“contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,”

“plan,” “positioned,” “potential,” “predict,” “forecast,” “guidance,” “look forward to,” “milestone,” “on track,” “outlook,”

“project,” “runway,” “seek,” “should,” “suggest,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future

events and future trends, or the negative of these terms or other comparable terminology. To the extent that statements contained in this press release are not descriptions of historical facts, they are forward-looking statements reflecting the

current beliefs and expectations of management. These forward-looking statements include, but are not limited to, statements regarding anticipated milestones, including technical milestones, data releases and public announcements related thereto;

Codexis’ expectation that its existing cash, cash equivalents and short-term investments will be sufficient to fund its planned operations, including the expenses associated with the build out of its GMP production facility; Codexis’

financial guidance; the receipt of required permits and approvals for, and the timing, cost and completion of, the retrofit construction of Codexis’ ECO GMP Manufacturing Center, the anticipated timing of the commencement of retrofit

construction and the facility being operational, and the intended use of the facility to supply siRNA material for preclinical investigations and clinical trials; Codexis’ ability to advance partnerships with drug innovators toward clinical

stage manufacturing agreements; Codexis’ ability to expand relationships with CDMO partners and to commence a strategic partner agreement; the availability of the remainder of Codexis’ loan facility for future drawdown, subject to

certain conditions; Codexis’ feasibility study; and the anticipated benefits, performance, sustainability and commercial potential of Codexis’ ECO Synthesis® Manufacturing Platform

and the anticipated level of customer interest in and adoption of Codexis’ technology. The forward-looking statements in this press release are subject to the safe harbor created by these sections, speak only as of the date of this press

release, and are qualified by the cautionary statements set forth below. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases,

beyond Codexis’ control and that could materially affect actual results. Factors that could materially affect actual results include, among others: Codexis’ dependence on its licensees and collaborators and the risk that collaborators

may terminate their development programs under their respective license agreements with Codexis; Codexis’ dependence on a limited number of products and customers, and potential adverse effects to Codexis’ business if its

customers’ products are not received well in the markets; Codexis’ ability to successfully develop and commercialize new technology and

Page | 3

products for its target markets, including its ECO Synthesis® Manufacturing Platform; the risk that competitors and potential competitors

who have greater resources and experience than Codexis may develop products and technologies that make Codexis’ products and technologies obsolete; Codexis’ ability to advance partnerships with drug innovators toward clinical stage

manufacturing agreements and to establish strategic partnerships with CDMOs; the timing, cost and successful completion of the retrofit construction of Codexis’ GMP facility and the risk that the facility may not achieve operational readiness

on the anticipated timeline; the risk that the FDA or other regulatory authorities may not accept enzymatically synthesized oligonucleotides or that the regulatory pathway for ECO Synthesis-derived products may be longer or more uncertain than

anticipated; risks relating to Codexis’ dependence on its GMP facility, and the risk of delays or cost overruns; the concentration of Codexis’ revenue in a limited number of contracts and milestones; Codexis’ potential need for

additional capital in the future in order to expand its business and the risk that additional capital may not be available on acceptable terms or at all; Codexis’ ability to comply with debt covenants under its loan facility and to satisfy

scheduled principal and interest payment obligations, and the effect of the terms of that facility on Codexis’ liquidity and operating flexibility; risks relating to Codexis’ ability to obtain, maintain, defend and enforce patents, trade

secrets and other intellectual property rights covering its technologies, and the risk of intellectual property infringement claims by third parties; Codexis’ dependence on key personnel and its ability to attract and retain qualified

employees; Codexis’ reliance on third-party suppliers; risks relating to cybersecurity incidents and data integrity; volatility in the market price of Codexis’ common stock and its ability to maintain compliance with Nasdaq listing

requirements; Codexis’ ability to accurately forecast financial and operational performance; the impact of market, political and economic conditions on Codexis’ business, financial condition and share price; and the impact of

international trade policies, including tariffs, sanctions and trade barriers, on Codexis’ business. Additional information about factors that could materially affect actual results can be found in Codexis’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 11, 2026, and in Codexis’ Quarterly Report on Form 10-Q for the quarterly period ended

September 30, 2026, to be filed with the SEC, in each case including under the caption “Risk Factors,” and in Codexis’ other filings with the SEC. Codexis expressly disclaims any intent or obligation to update these

forward-looking statements, except as required by law. Codexis’ results presented in this press release are not necessarily indicative of Codexis’ operating results for any future periods.

For More Information

Investor Contact

Georgia Erbez

(650)

421-8100

ir@codexis.com

Page | 4

Codexis, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

(In

Thousands, Except Per Share Amounts)

Three Months Ended September 30,

Nine Months Ended September 30,

2026

2025

2026

2025

Revenues:

Product revenue

$

15,740

$

6,807

$

36,149

$

20,246

Research and development revenue

3,522

1,794

13,277

11,226

Total revenues

19,262

8,601

49,426

31,472

Costs and operating expenses:

Cost of product revenue

4,014

2,465

9,590

7,295

Research and development

12,587

13,868

35,741

40,586

Selling, general and administrative

10,097

11,217

30,803

35,889

Total costs and operating expenses

26,698

27,550

76,134

83,770

Loss from operations

(7,436

)

(18,949

)

(26,708

)

(52,298

)

Interest income

658

634

1,859

1,969

Interest and other expense, net

(1,341

)

(1,292

)

(3,933

)

(3,217

)

Loss before income taxes

(8,119

)

(19,607

)

(28,782

)

(53,546

)

Provision for income taxes

9

8

55

29

Net loss

$

(8,128

)

$

(19,615

)

$

(28,837

)

$

(53,575

)

Net loss per share, basic and diluted

$

(0.08

)

$

(0.22

)

$

(0.30

)

$

(0.62

)

Weighted average common stock shares used in computing net loss per share, basic and

diluted

107,259

90,251

96,507

86,045

Codexis, Inc.

Condensed Consolidated Statements of Comprehensive Loss

(Unaudited)

(In

Thousands)

Three Months Ended September 30,

Nine Months Ended September 30,

2026

2025

2026

2025

Net loss

$

(8,128

)

$

(19,615

)

$

(28,837

)

$

(53,575

)

Other comprehensive income (loss):

Unrealized income (loss) on

available-for-sale short-term investments, net of tax

(42

)

15

(63

)

(40

)

Comprehensive loss

$

(8,170

)

$

(19,600

)

$

(28,900

)

$

(53,615

)

Page | 5

Codexis, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(In

Thousands)

September 30, 2026

December 31, 2025

Assets

Current assets:

Cash and cash equivalents

$

29,213

$

50,793

Restricted cash, current

—

478

Short-term investments

43,446

27,416

Financial assets:

Accounts receivable

6,499

8,757

Contract assets

8,590

492

Unbilled receivables

604

1,480

Total financial assets

15,693

10,729

Less: allowances

(43

)

(43

)

Total financial assets, net

15,650

10,686

Inventories

2,096

1,817

Prepaid expenses and other current assets

5,360

5,626

Total current assets

95,765

96,816

Restricted cash

1,612

1,612

Investment in non-marketable equity securities

2,498

2,498

Right-of-use

assets - Operating leases, net

27,659

30,501

Property and equipment, net

13,329

13,024

Goodwill

2,463

2,463

Other non-current assets

895

883

Total assets

$

144,221

$

147,797

Liabilities and Stockholders’ Equity

Current liabilities:

Accounts payable

$

5,760

$

1,554

Accrued compensation

8,751

11,042

Other accrued liabilities

4,105

2,768

Current portion of lease obligations - Operating leases

2,946

2,944

Current portion of long-term debt

11,793

—

Deferred revenue

735

7,009

Total current liabilities

34,090

25,317

Deferred revenue, net of current portion

—

360

Long-term lease obligations - Operating leases

28,043

30,159

Long-term debt

29,485

40,105

Other long-term liabilities

1,365

1,327

Total liabilities

92,983

97,268

Stockholders’ equity:

Common stock

11

9

Additional paid-in capital

686,899

657,292

Accumulated other comprehensive income (loss)

(55

)

8

Accumulated deficit

(635,617

)

(606,780

)

Total stockholders’ equity

51,238

50,529

Total liabilities and stockholders’ equity

$

144,221

$

147,797

Page | 6

GRAPHIC

GRAPHIC

Filename: g189706g1113012950841.jpg · Sequence: 6

Binary file (5980 bytes)

Download g189706g1113012950841.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.3

Document and Entity Information

Nov. 12, 2026

Cover [Abstract]

Amendment Flag

false

Entity Central Index Key

0001200375

Document Type

8-K

Document Period End Date

Nov. 12, 2026

Entity Registrant Name

Codexis, Inc.

Entity Incorporation State Country Code

DE

Entity File Number

001-34705

Entity Tax Identification Number

71-0872999

Entity Address, Address Line One

200 Penobscot Drive

Entity Address, City or Town

Redwood City

Entity Address, State or Province

CA

Entity Address, Postal Zip Code

94063

City Area Code

(650)

Local Phone Number

421-8100

Written Communications

false

Soliciting Material

false

Pre Commencement Tender Offer

false

Pre Commencement Issuer Tender Offer

false

Security 12b Title

Common Stock, par value $0.0001 per share

Trading Symbol

CDXS

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

X

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

na

Period Type:

duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration